Real-World Effectiveness Outcomes in Patients Diagnosed with Metastatic Triple-Negative Breast Cancer

Skinner, Karen E; Haiderali, Amin; Huang, Min; Schwartzberg, Lee S.

doi:10.2217/fon-2020-1021

Cited by 16 publications

(14 citation statements)

References 20 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were consistent with previous studies 1 , 5 – 8 , 15 , 24 . The survival rate of mTNBC (10.81%) was comparable to those found in other countries, ranging from 4% to 20% 3 , 9 – 13 .…”

Section: Discussionsupporting

confidence: 79%

“…In German, the 5-year overall survival rate was 75.8% and 84.8% in TNBC and non-TNBC patients, respectively 8 . The 5-year overall survival rate in metastatic triple-negative breast cancer (mTNBC) patients was 4–20% in western countries 3 , 9 – 13 . In Taiwan, patients with TNBC account for 15–20% of all breast cancer patients 14 – 16 , which is similar to findings in western countries 1 – 3 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Hsu

Chang

Cheng

2022

Sci Rep

View full text Add to dashboard Cite

Individuals diagnosed with metastatic triple-negative breast cancer (mTNBC) suffer worse survival rates than their metastatic non-TNBC counterparts. There is little information on survival, treatment patterns, and medical costs of mTNBC patients in Asia. Therefore, this study aimed to examine 5-year survival, regimens of first-line systemic therapy, and healthcare costs of mTNBC patients in Taiwan. Adult females newly diagnosed with TNBC and non-TNBC as well as their survival data, treatment regimens and costs of health services were identified and retrieved from the Cancer Registry database, Death Registry database, and National Health Insurance (NHI) claims database. A total of 9691 (19.27%) women were identified as TNBC among overall BC. The 5-year overall survival rate of TNBC and non-TNBC was 81.28% and 86.50%, respectively, and that of mTNBC and metastatic non-TNBC was 10.81% and 33.46%, respectively. The majority of mTNBC patients received combination therapy as their first-line treatment (78.14%). The 5-year total cost in patients with metastatic non-TNBC and with mTNBC was NTD1,808,693 and NTD803,445, respectively. Higher CCI scores were associated with an increased risk of death and lower probability of receiving combination chemotherapy. Older age was associated with lower 5-year medical costs. In sum, mTNBC patients suffered from poorer survival and incurred lower medical costs than their metastatic non-TNBC counterparts. Future research will be needed when there are more treatment options available for mTNBC patients.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Hsu

Chang

Cheng

2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This is not only reflected by the poor OS, but also by the lack of evidence of first-line treatment initiation in a notable proportion of patients in both racial groups. Consistent with a previous study that examined treatment patterns in real-world patients with mTNBC treated in the community setting ( 10 ), we found one in four patients with mTNBC in both racial groups had missing documentation of anticancer treatment in the Flatiron database. It is important to note that some patients with mTNBC may have forgone treatment due to poor performance status and concerns about treatment tolerance.…”

Section: Discussionsupporting

confidence: 90%

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices

Tan¹,

Cassoli²,

Yan³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

ObjectiveReal-world data characterizing differences between African American (AA) and White women with metastatic triple-negative breast cancer (mTNBC) are limited. Using 9 years of data collected from community practices throughout the United States, we assessed racial differences in the proportion of patients with mTNBC, and their characteristics, treatment, and overall survival (OS).MethodsThis retrospective study analyzed de-identified data from 2,116 patients with mTNBC in the Flatiron Health database (January 2011 to March 2020). Characteristics and treatment patterns between AA and White patients with mTNBC were compared using descriptive statistics. OS was examined using Kaplan-Meier analysis and a multivariate Cox proportional hazards regression model.ResultsAmong patients with metastatic breast cancer, more AA patients (23%) had mTNBC than White patients (12%). This difference was particularly pronounced in patients who lived in the Northeast, were aged 45–65, had commercial insurance, and had initial diagnosis at stage II. AA patients were younger and more likely to have Medicaid. Clinical characteristics and first-line treatments were similar between AA and White patients. Unadjusted median OS (months) was shorter in AA (10.3; 95% confidence interval [CI]: 9.1, 11.7) vs. White patients (11.9; 95% CI: 10.9, 12.8) but not significantly different. After adjusting for potential confounders, the hazard ratio for OS was 1.09 (95% CI: 0.95, 1.25) for AA vs. White patients.ConclusionsThe proportion of patients with mTNBC was higher in AA than White mBC patients treated in community practices. Race did not show an association with OS. Both AA and White patients with mTNBC received similar treatments. OS was similarly poor in both groups, particularly in patients who had not received any documented anti-cancer treatment. Effective treatment remains a substantial unmet need for all patients with mTNBC.

show abstract

“…Chemotherapy is currently the standard-of-care for metastatic (m)TNBC patients; however, it is associated with short initial responses and poor prognosis [ 1 ]. Treatment options for mTNBC are increasing with FDA-approved immune checkpoint blockade-based treatments (atezolizumab), poly ADP-ribose polymerase (PARP) inhibitors (i.e., olaparib), and more recently, the novel antibody-drug conjugate, sacituzumab govitecan [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report

et al. 2022

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is highly aggressive disease that is often refractory to surgery and multiple lines of therapy. Although the repertoire of FDA-approved treatments has expanded, there is an unmet need for biomarkers that can aid in appropriate selection and timing of therapy. We present a case of highly aggressive treatment-resistant TNBC that employed a comprehensive genomic profiling (CGP)-based assay to identify therapeutic targets, followed by longitudinal circulating tumor DNA (ctDNA) testing. For this, a tumor-naïve next-generation sequencing-based targeted panel was used to aid in therapy selection, along with longitudinal personalized and tumor-informed ctDNA testing to monitor tumor response to treatment. Longitudinal ctDNA testing using the tumor-informed assay detected post-surgical molecular residual disease, and rise in ctDNA levels during the surveillance period provided rationale for switching between four lines of therapy. Overall, the combined use of CGP assay with longitudinal ctDNA testing resulted in a potential prolonged survival in this highly aggressive case of TNBC.

show abstract

Real-World Effectiveness Outcomes in Patients Diagnosed with Metastatic Triple-Negative Breast Cancer

Cited by 16 publications

References 20 publications

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices

Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report

Contact Info

Product

Resources

About